Safety of Intranasal Irrigation Probiotics in Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02933918|
Recruitment Status : Not yet recruiting
First Posted : October 14, 2016
Last Update Posted : October 14, 2016
Chronic rhinosinusitis (CRS) is one of the most common chronic diseases, affecting the quality of life of patients who suffer. Despite medical and surgical treatments available, there are a significant number of people suffering from CRS refractory to these standard treatments.
A preliminary clinical trial conducted at CHUM Hôtel-Dieu, has allowed us to evaluate the therapeutic potential of intranasal irrigation of probiotics in patients with CRS. This treatment administered twice daily for 14 days was well tolerated and resulted in improved chronic rhinosinusitis symptoms.
Prior to deployment on a larger scale, the safety of this therapy must be confirmed in a healthy population, free of sinus disease. Therefore, this study aims to assess the safety of the use of probiotic intranasal irrigation in healthy volunteers.
|Condition or disease||Intervention/treatment||Phase|
|Sinusitis||Other: Probiotics||Phase 1|
If the participant (healthy volunteer) agrees to participate in the study, and after signing the information consent form, her/his participation in this project will consist to receive the experimental treatment of probiotics, to come to three (3) medical assessment visits at CHUM Hôtel-Dieu, over a period of time of three (3) weeks, and answer to one (1) phone call.
This study will include the following four (4) periods :
- determination of eligibility period - Day 0
- saline irrigation period (for 7 days) - between Day 0 and Day 7
- probiotic treatment period ( for 7 days) - between Day 7 and Day 14
- telephone follow-up period - Day 21
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety of Intranasal Irrigation Probiotics in Healthy Volunteers|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||November 2017|
|Experimental: Probiotics||Other: Probiotics|
- Change in sense of smell using the "University of Pennsylvania smell identification test (UPSIT-40)" [ Time Frame: Change from baseline sense of smell at Day 7and Day 14 ]A smell test will be conducted using "scratch and sniff fragrance strips" (UPSIT-40), where 40 odors are presented. The participant must choose one of four choices for each odor, even if she/he is unable to identify the smell.
- Change in sino-nasal symptomatology using questionnaire [ Time Frame: Change from baseline sino-nasal symptomatology at Day 7, Day 14 and Day 21 ]This questionnaire evaluates 5 items (nasal congestion, facial pain, headache, need to blow nose, post-nasal drip) on 0-3 scale (0= none; 1=mild; 2=moderate; 3= severe).
- Change in Eustachian tube symptomatology using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7) [ Time Frame: Change from baseline Eustachian tube symptomatology at Day 7, Day 14 and Day 21 ]Using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7).
- Change in ear examination [ Time Frame: Change from baseline ear examination at Day 7 and Day 14 ]
- Change in anterior rhinoscopy [ Time Frame: Change from baseline anterior rhinoscopy at Day 7 and Day 14 ]
- Change in microbiome composition [ Time Frame: Change from baseline microbiome composition at Day 7 and Day 14 ]Evaluation of the difference in the percentage of the bacterial population before and after treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933918
|Contact: Leandra Mfuna Endam, Msc||514-890-8000 ext email@example.com|
|Centre Hospitalier de l'Université de Montréal, Hôtel-Dieu||Not yet recruiting|
|Montreal, Quebec, Canada, H2W 1T8|
|Contact: Leandra Mfuna Endam, Msc 514-890-8000 ext 14170 firstname.lastname@example.org|
|Principal Investigator: Martin Yvon Desrosiers, MD|
|Study Chair:||Martin Yvon Desrosiers, MD||Probionase Therapies Inc.|